March 2, 2004
BioLase Technology, Inc. Announces Offering Of 2,807,500 Shares
BioLase Technology, Inc. (NASDAQ:BLTI) today announced the pricing of its previously announced public offering of common stock at $18.50 per share, before underwriting discounts and commissions. The offering consists of 2,807,500 shares of common stock, including 2,500,000 newly issued shares offered by the Company and 307,500 shares offered by a selling stockholder. The offering is expected to close on March 3, 2004. In addition, the underwriters have a 30-day period in which to exercise an option to purchase from the Company up to 421,125 additional newly issued shares of common stock to cover over- allotments, if any. Needham & Company, Inc. is acting as lead manager in the offering, and the co-managers are William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. The offering of these securities is made only by means of a prospectus, which may be obtained from Needham & Company, Inc., 445 Park Avenue, New York City, New York 10022, William Blair & Company, L.L.C., 222 West Adams Street, Chicago, Illinois 60606, and Oppenheimer & Co. Inc., 125 Broad Street, 16th Floor, New York, NY 10004.
Source: BioLase Technology, Inc.
CONTACT: Jeffrey W. Jones, President & CEO of BioLase Technology, Inc.,
+1-949-361-1200, jjones@biolase.com; or Investor Relations, Linda Decker of
Porter, LeVay & Rose, Inc., +1-212-564-4700, Linda@plrinvest.com, for BioLase
Technology, Inc.
Web site: http://www.biolase.com/
March 2, 2004
Isolagen Announces Additional Support for Results
Isolagen, Inc. (AMEX:ILE) , a biopharmaceutical company specializing in the development and commercialization of autologous (a patient's own) cellular therapy for hard and soft tissue regeneration ("the Isolagen Process"), today announced additional findings from further analysis of results from a 6-month double- blind clinical study in which their proprietary treatment successfully reversed gingival recession and improved deep-periodontal pocketing. The clinical examinations of 176 intra-oral sites in 21 subjects were conducted at the University of Texas Health Science Center (UTHSC) Dental Branch and represent the company's first set of clinical data in the oral health care market.
Previously, the Company announced that the study results demonstrated significant improvement in the oral therapeutic treatment of periodontal (gum) disease by reducing "deep pocket" areas in a majority of sites, whereas placebo treated sites showed a nominal improvement. A paired T-test demonstrates that Isolagen response exceeded placebo response by an average of 1.1 mm, (p=0.0005). As part of the ongoing analysis of this Dental study, different subsets of the data were and are being analyzed. Dr. Otis Bouwsma, Principal Investigator, recently completed an analysis of the pockets greater than or equal to 5 mm in depth. The results of this analysis are clinically important because deep pockets of this magnitude form the watershed between those patients who can be treated medically with improved hygiene and other therapies and those who may need to be treated surgically with a range of therapies from Root planing and scaling to surgical graft of tissue to the exposed roots.
The net improvement was 2.4 mm (Signed P Test 0.0625) based on an examination of the results in the treated and placebo groups of the study. This latest analysis indicates that a patient with a 7 mm pocket could experience an average decrease in pocket depth to 4.6 mm. Patients with pocket depth of less that 5 mm face a more benign problem and have their treatment options including less expensive and less painful non-surgical treatment.
"We continue to be pleased with the results of this study," said Michael Macaluso, CEO and President. "The fact that we might be able to offer dental patients a treatment that will help them avoid painful, expensive surgery in the years to come is a great step forward."
"Deep pocket disease can lead to erosion of the bone, pain and tooth loss. We are still waiting to see what effect the Isolagen Process may have on the underlying bone in patients with deep pocket disease. However, the results of this study indicate that the Isolagen Process can arrest, and in some cases reverse, the progress of the disease," reported Vaughan Clift, MD., Medical Director.
Isolagen's corporate headquarters are located in Houston, TX. For further information, please see www.isolagen.com .
Source: Isolagen, Inc.
CONTACT: Michael Macaluso, CEO, or Jeffrey W. Tomz, CFO, both of
Isolagen, Inc., +1-713-780-4754
Web site: http://www.isolagen.com/